期刊文献+

脱甲基化药物5-氮-2'-脱氧胞苷抑制前列腺癌细胞增殖作用的分析

Study on the effect of demethylation of drug 5-aza-2'-deoxycytidine on the suppression of growth of prostate carcinoma cells
下载PDF
导出
摘要 目的探讨脱甲基化药物5-氮-2'-脱氧胞苷(DAC)对前列腺癌细胞的生长抑制效果。方法利用WST-1法测定DAC对前列腺癌细胞株的增殖影响作用,流式细胞仪检测DAC在诱导细胞凋亡与细胞周期捕获中的效果,同时应用半胱天冬酶(Caspase)活性分析与增殖细胞核抗原(PCNA)表达来进一步阐明DAC的作用机制。结果DAC同时对激素依赖型及激素非依赖性型前列腺癌细胞株具有显著的生长抑制效果,DAC的作用机制主要是通过诱导G2/M期的细胞捕获实现,而不是通过凋亡诱导。结论脱甲基化药物DAC可抑制前列腺癌细胞的生长,将来可能成为治疗前列腺癌并改善预后的一种新型药物。 Objective To explore the effect of 5- aza- 2'- deoxycytidine( DAC),a DNA methyltransferase inhibitor,on the growth of prostate carcinoma( PC) cell lines. Methods The cytotoxicity of DAC on PC cell lines had been measured by using WST- 1 assay. Its effect on induction of apoptosis and arrest of cell cycle had been analyzed by flow cytometric analysis. Caspase activity and PCNA expression were also applied to clarify the mechanism of DAC against PC. Results The suppression of growth had been confirmed by DAC in test for PC cell lines,while the inhibition of proliferation by DAC was through inducing arrest of G2 / M cell cycle but not by inducing apoptosis. Conclusion DAC has the effect of suppression on growth of PC cell lines and it may be a new strategy to treat prostate malignancy in the future.
出处 《临床和实验医学杂志》 2015年第7期527-530,共4页 Journal of Clinical and Experimental Medicine
基金 国家自然科学基金资助项目(No.30801139)
关键词 前列腺癌 甲基化 DAC Prostate carcinoma Methylation DAC
  • 相关文献

参考文献15

  • 1Weir HK, Thun M J, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975 - 2000, featuring the uses of surveillance da- ta for cancer prevention and control [ J ]. Natl Cancer lnst, 2003,95 (17) : 1276 - 1299.
  • 2叶定伟,李长岭.前列腺癌发病趋势的回顾和展望[J].中国癌症杂志,2007,17(3):177-180. 被引量:119
  • 3Morganti AG, Massaccesi M, Caravatta L, et al. Radiotherapy and con- current metronomic chemotherapy in hormone -refractory prostate carci- noma: a Phase I study [ J ]. Anticancer Res, 2013,33 ( 10 ) : 4585 - 4589.
  • 4Aragon - Ching JB, Dahut WL. Chemotherapy in Androgen - Independ- ent Prostate Cancer (AIPC) : What's next after taxane progression [ J ] Cancer Ther,2007,5A : 151 - 160.
  • 5Madan RA, Lieberman R, Gulley JL, et al. Significant prostate - spe- cific antigen (PSA) response to low - dose ketoconazole in a patient with non - metastatic androgen - independent prostate cancer ( AIPC ) and a review of the literature[J]. Am J Ther,2007,14 (3) :310 - 313.
  • 6Jeronimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer [ J ]. Clin Cancer Res, 2004, 10 (24) :8472 - 8476.
  • 7Shang DH, Ito N, Kamoto T, et al. Demethylating agent 5 - aza - 2"- de- oxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel [ J ]. Urology ,2007,69 (5) :1007 - 1012.
  • 8Inoue T, Yoshida T, Shimizu Y, et al. Requirement of androgen - de- pendent activation of protein kinase Czeta for androgen - dependent cell proliferation in LNCap Cells and its roles in transition to androgen - in- dependent cells [ J ]. Mol Endocrinol, 2006,20 ( 12 ) : 3053 - 3069.
  • 9Perry AS, Foley R, Woodson K, et al. The emerging roles of DNA methylation in the clinical management of prostate cancer [ J ]. Endocr Relat Cancer,2006,13 ( 2 ) : 357 - 377.
  • 10Hopkins TG, Burns PA, Routledge MN. DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer[ J ]. Urology,2007,69 (1) :11 -16.

二级参考文献5

共引文献118

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部